Skip to main content

Gary H. Gibbons, M.D.

Gary H. Gibbons
Senior Investigator
Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch

Cardiovascular Disease Section

A.B. Princeton University, 1978
M.D. Harvard University, 1984

T: (301) 496-5166
F: (301) 402-0818
Building 31, Room 5A48E
31 CENTER DR, MSC 2486
BETHESDA, MD 20892-2486

Selected Publications


The Cardiovascular Disease Section (CVDS) at the National Human Genome Research Institute specializes in multi-disciplinary translational research, in concordance with the traditional genotype-to-phenotype (G2P) imputations of the NHGRI as a whole. More specifically, CVDS is utilizing a combination of noninvasive cardiovascular imaging, massively parallel sequencing, biomedical informatics, systems biology, and genomic epidemiology to conduct ultra-large-scale data analyses. The mission of the CVDS team is to understand the relationships and interdependencies between clinical phenotypes, human behavior, biosurveillance, molecular interactions, as well as genomic and social determinants on gene expression and their contribution to health disparities in cardiovascular disease. Our objective is to develop community-based cohorts and novel genomic science resources for defining the biological significance of ancestry-related genomic variation in African-Americans. Through this process, we aim to build a shared-use research infrastructure that supports leading-edge cardiovascular science.

A long-standing interest of Dr. Gibbons is to mentor and develop a critical mass of talented investigators who will emerge as leaders of independent research programs and cross-disciplinary, collaborative research teams to further elucidate the underpinnings of racial and ethnic disparities in cardiovascular health.


Gary H. Gibbons, M.D., is director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), where he oversees the third largest institute at the NIH, with an annual budget of more than $3 billion and a staff of 917 federal employees. The NHLBI provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. Prior to being named director of the NHLBI, Gibbons served as a member of the National Heart, Lung, and Blood Advisory Council (NHLBAC) from 2009-2012. He was also a member of the NHLBI Board of Extramural Experts (BEE), a working group of the NHLBAC. Before joining the NHLBI, Gibbons served as the founding director of the Cardiovascular Research Institute, chairperson of the Department of Physiology, and professor of physiology and medicine at the Morehouse School of Medicine, in Atlanta.

Under his leadership of the Cardiovascular Research Institute, Gibbons directed NIH-funded research in the fields of vascular biology, genomic medicine, and the pathogenesis of vascular diseases. During his tenure, the Cardiovascular Research Institute emerged as a center of excellence, leading the way in discoveries related to the cardiovascular health of minority populations. Gibbons received several patents for innovations derived from his research in the fields of vascular biology and the pathogenesis of vascular diseases.

Gibbons earned his undergraduate degree from Princeton University in Princeton, N.J., and graduated magna cum laude from Harvard Medical School in Boston. He completed his residency and cardiology fellowship at the Harvard-affiliated Brigham and Women's Hospital in Boston. Prior to joining the Morehouse School of Medicine in 1999, Gibbons was a member of the faculty at Stanford University in Stanford, Calif., from 1990-1996, and at Harvard Medical School from 1996-1999. 

Throughout his career, Gibbons has received numerous honors, including election to the Institute of Medicine of the National Academies of Sciences; selection as a Robert Wood Johnson Foundation Minority Faculty Development Awardee; selection as a Pew Foundation Biomedical Scholar; and recognition as an Established Investigator of the American Heart Association (AHA).

Scientific Summary

Top of page

Last Updated: December 8, 2014